Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
Sign Up to like & getrecommendations! Published in 2021 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2021.10.007
Abstract: BACKGROUND AIMS Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single leukemia-associated antigen with chimeric antigen receptor (CAR) T cells have met with limited success, due in part to heterogeneous… read more here.
Keywords: cll; antigen; cd33; myeloid ... See more keywords
Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Drug Delivery"
DOI: 10.1080/10717544.2017.1333170
Abstract: Abstract A novel niosomal delivery system was designed and investigated for the targeted delivery of daunorubicin (DNR) against acute myeloid leukemia (AML). Anti-CD123 antibodies conjugated to Mal-PEG2000-DSPE were incorporated into normal niosomes (NS) via a… read more here.
Keywords: antibody; cd123; anti cd123; daunorubicin ... See more keywords
Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics
Sign Up to like & getrecommendations! Published in 2017 at "Drug Delivery"
DOI: 10.1080/10717544.2017.1367976
Abstract: Abstract Since conventional chemotherapy for acute myeloid leukemia (AML) has its limitations, a theranostic platform with targeted and efficient drug transport is in demand. In this study, we developed the first CD123 (AML tumor marker)… read more here.
Keywords: drug; cd123; targeted drug; cd123 aptamer ... See more keywords
Expanding the Immunophenotypic Spectrum of Neoplastic and Reactive Plasmacytoid Dendritic Cells.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqac174
Abstract: OBJECTIVES Targeted therapies for blastic plasmacytoid dendritic cell neoplasm (BPDCN) have presented a diagnostic dilemma for differentiating residual BPDCN from reactive plasmacytoid dendritic cells (pDCs) because these conditions have a similar immunoprofile, necessitating discovery of… read more here.
Keywords: reactive plasmacytoid; sox4; plasmacytoid dendritic; dendritic cells ... See more keywords
EXTH-114. Dual CD123 and B7-H3 CAR T Cells Potentiate Immune Responses and Remodel the Tumor Microenvironment in Pediatric Gliomas
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.1447
Abstract: Pediatric high-grade gliomas (pHGG) are characterized by an immunologically cold and highly immunosuppressive tumor microenvironment (TME). It is dominated by M2-like tumor-associated macrophages (TAMs), which impair CAR T-cell function and persistence. However, broad myeloid targeting… read more here.
Keywords: car cell; car; tumor; car cells ... See more keywords
IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of cutaneous pathology"
DOI: 10.1111/cup.14439
Abstract: We highlight the utility of interferon regulatory factor 8 (IRF8), a novel marker of monocytic and dendritic cell lineages, in the diagnosis of a case of blastic plasmacytoid dendritic cell neoplasm (BPDCN) presenting initially in… read more here.
Keywords: marker; irf8; dendritic cell; expression ... See more keywords
P09.12 Bifunctional SIRPα-CD123 fusion antibody for the elimination of acute myeloid leukemia stem cells
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-itoc7.112
Abstract: Despite advances in the development of novel strategies against acute myeloid leukemia (AML), treatment options are limited and most patients relapse. Relapse occurs due to the persistence of chemotherapy-resistant leukemic stem cells (LSCs), which re-initiate… read more here.
Keywords: none; sirp cd123; antibody; cd123 antibody ... See more keywords
Abstract 597: Bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecules for redirected T-cell cytotoxicity in hematological malignancies
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-597
Abstract: Introduction: CD123 is a component of the IL-3 receptor expressed in several hematological malignancies including AML, ALL, HCL, and MDS. CD123 is a compelling target in AML due to its overexpression on AML blasts as… read more here.
Keywords: anti; cd123; apvo436 apvo437; cell ... See more keywords
A Rare Case of Hairy Cell Leukemia with Unusual Loss of CD123 Associated with COVID-19 at the Time of Presentation
Sign Up to like & getrecommendations! Published in 2020 at "Case Reports in Oncology"
DOI: 10.1159/000512830
Abstract: Coronavirus disease 2019 (COVID-19) pandemic has been a serious threat and has been reported with different presentations and complications. Older age, along with comorbidities such as diabetes, hypertension, or cardiac disease, increases the risk factors… read more here.
Keywords: loss cd123; hairy; case; cd123 ... See more keywords
Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-126869
Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with historically poor outcomes and no established standard of care. Nearly 100% of patients with BPDCN overexpress CD123, and targeting CD123 has therefore… read more here.
Keywords: research; cd123; bpdcn; research funding ... See more keywords
CD123-targeted radiotheranostics of Acute Myeloid Leukemia with 89Zr/177Lu-labeled pivekimab
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5052
Abstract: Introduction CD123, the interleukin-3 receptor alpha chain, is highly-expressed on AML blasts and stem cells but less on normal counterparts, making it an attractive target for targeted therapy. Pivekimab sunirine (IMGN632) is an antibody–drug conjugate… read more here.
Keywords: dfo pive; 177lu dtpa; 89zr dfo; cd123 ... See more keywords